Biohaven Ltd. presented updates on its portfolio progress and early patient data from its priority degrader programs at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted positive early clinical experience with its proprietary MoDE™ and next-generation TRAP™ degraders, which showed rapid removal of circulating disease-causing proteins and robust clinical improvement in patients. Biohaven also announced a memorandum of understanding with King Abdullah University of Science and Technology (KAUST) to collaborate on next-generation degrader discovery efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE60727) on January 12, 2026, and is solely responsible for the information contained therein.